| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
GSF-Institute for Molecular Virology, 81675 Munich [I. D.,V. E., G. S.]; Bavarian Nordic Research Institute, 81675 Munich [I. D.]; TUM-Institute for Virology, 81675 Munich [I. D., V. E.]; Institute for Immunology, TU Dresden, 01101 Dresden [M. S., P. R.]; and Department of Hematology, Johannes Gutenberg-University, 55101 Mainz [E. A., T. W., C. H., M. T.], Germany
Vaccination with tumor-associated antigens is a promising approach for cancer immunotherapy. Because the majority of these antigens are normal self antigens, they may require suitable delivery systems to promote their immunogenicity. A recombinant vector based on the modified vaccinia virus Ankara (MVA) was used for expression of human tyrosinase, a melanoma-specific differentiation antigen, and evaluated for its efficacy as an antitumor vaccine. Stable recombinant viruses (MVA-hTyr) were constructed that have deleted the selection marker lacZ and efficiently expressed human tyrosinase in primary human cells and cell lines. Tyrosinase-specific human CTLs were activated in vitro by MVA-hTyr-infected, HLA-A*0201-positive human dendritic cells. Importantly, an efficient tyrosinase- and melanoma-specific CTL response was induced in vitro using MVA-hTyr-infected autologous dendritic cells as activators for peripheral blood mononuclear cells derived from HLA-A*0201-positive melanoma patients despite prior vaccination against smallpox. Immunization of HLA-A*0201/Kb transgenic mice with MVA-hTyr induced A*0201-restricted CTLs specific for the human tyrosinase-derived peptide epitope 369–377. These in vivo primed CTLs were of sufficiently high avidity to recognize and lyse human melanoma cells, which present the endogenously processed tyrosinase peptide in the context of A*0201. Tyrosinase-specific CTL responses were significantly augmented by repeated vaccination with MVA-hTyr. These findings demonstrate that HLA-restricted CTLs specific for human tumor-associated antigens can be efficiently generated by immunization with recombinant MVA vaccines. The results are an essential basis for MVA-based vaccination trials in cancer patients.
This article has been cited by other articles:
|
|
 |
|
  P. S. Hahnel, S. Thaler, E. Antunes, C. Huber, M. Theobald, and M. Schuler Targeting AKT Signaling Sensitizes Cancer to Cellular Immunotherapy Cancer Res., May 15, 2008; 68(10): 3899 - 3906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Marques, P. S. Hahnel, C. Wolfel, S. Thaler, C. Huber, M. Theobald, and M. Schuler An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression Blood, February 1, 2008; 111(3): 1413 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gasteiger, W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler Cross-Priming of Cytotoxic T Cells Dictates Antigen Requisites for Modified Vaccinia Virus Ankara Vector Vaccines J. Virol., November 1, 2007; 81(21): 11925 - 11936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kastenmuller, G. Gasteiger, J. H. Gronau, R. Baier, R. Ljapoci, D. H. Busch, and I. Drexler Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination J. Exp. Med., September 3, 2007; 204(9): 2187 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chahroudi, D. A. Garber, P. Reeves, L. Liu, D. Kalman, and M. B. Feinberg Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus ankara and vaccinia virus. J. Virol., September 1, 2006; 80(17): 8469 - 8481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Su, J. Kuball, A.-P. Barreiros, D. Gottfried, E. A. Ferreira, M. Theobald, P. R. Galle, D. Strand, and S. Strand Nitric Oxide Promotes Resistance to Tumor Suppression by CTLs J. Immunol., April 1, 2006; 176(7): 3923 - 3930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Moran, M. Collier, K. P. McKinnon, N. L. Davis, R. E. Johnston, and J. S. Serody A Novel Viral System for Generating Antigen-Specific T Cells J. Immunol., September 1, 2005; 175(5): 3431 - 3438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig, J. Mages, C. Staib, M. H. Lehmann, R. Lang, and G. Sutter Role of Viral Factor E3L in Modified Vaccinia Virus Ankara Infection of Human HeLa Cells: Regulation of the Virus Life Cycle and Identification of Differentially Expressed Host Genes J. Virol., February 15, 2005; 79(4): 2584 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al. Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Makitalo, P. Lundholm, J. Hinkula, C. Nilsson, K. Karlen, A. Morner, G. Sutter, V. Erfle, J. L. Heeney, B. Wahren, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen J. Gen. Virol., August 1, 2004; 85(8): 2407 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cosma, S. Buhler, R. Nagaraj, C. Staib, A.-L. Hammarin, B. Wahren, F. D. Goebel, V. Erfle, and G. Sutter Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus Clin. Vaccine Immunol., March 1, 2004; 11(2): 406 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Herrmann, H.-A. Lehr, I. Drexler, G. Sutter, J. Hengstler, U. Wollscheid, and B. Seliger HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway Cancer Res., January 1, 2004; 64(1): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fleischer, B. Schmidt, W. Kastenmuller, D. H. Busch, I. Drexler, G. Sutter, M. Heike, C. Peschel, and H. Bernhard Melanoma-Reactive Class I-Restricted Cytotoxic T Cell Clones Are Stimulated by Dendritic Cells Loaded with Synthetic Peptides, but Fail to Respond to Dendritic Cells Pulsed with Melanoma-Derived Heat Shock Proteins In Vitro J. Immunol., January 1, 2004; 172(1): 162 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hornemann, O. Harlin, C. Staib, S. Kisling, V. Erfle, B. Kaspers, G. Hacker, and G. Sutter Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L J. Virol., August 1, 2003; 77(15): 8394 - 8407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bukur, V. Rebmann, H. Grosse-Wilde, H. Luboldt, H. Ruebben, I. Drexler, G. Sutter, C. Huber, and B. Seliger Functional Role of Human Leukocyte Antigen-G Up-Regulation in Renal Cell Carcinoma Cancer Res., July 15, 2003; 63(14): 4107 - 4111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meiser, D. Boulanger, G. Sutter, and J. Krijnse Locker Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release J. Gen. Virol., June 1, 2003; 84(6): 1383 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Espenschied, J. Lamont, J. Longmate, S. Pendas, Z. Wang, D. J. Diamond, and J. D. I. Ellenhorn CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model J. Immunol., March 15, 2003; 170(6): 3401 - 3407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Woodberry, J. Gardner, S. L. Elliott, S. Leyrer, D. M. Purdie, P. Chaplin, and A. Suhrbier Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias J. Immunol., March 1, 2003; 170(5): 2599 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Ritz, I. Drexler, D. Sutter, R. Abele, C. Huber, and B. Seliger Impaired Transporter Associated with Antigen Processing (TAP) Function Attributable to a Single Amino Acid Alteration in the Peptide TAP Subunit TAP1 J. Immunol., January 15, 2003; 170(2): 941 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Drexler, C. Staib, W. Kastenmuller, S. Stevanovic', B. Schmidt, F. A. Lemonnier, H.-G. Rammensee, D. H. Busch, H. Bernhard, V. Erfle, et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines PNAS, January 7, 2003; 100(1): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Sancho, S. Schleich, G. Griffiths, and J. Krijnse-Locker The Block in Assembly of Modified Vaccinia Virus Ankara in HeLa Cells Reveals New Insights into Vaccinia Virus Morphogenesis J. Virol., July 17, 2002; 76(16): 8318 - 8334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Ober, P. Bruhl, M. Schmidt, V. Wieser, W. Gritschenberger, S. Coulibaly, H. Savidis-Dacho, M. Gerencer, and F. G. Falkner Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus Ankara J. Virol., June 27, 2002; 76(15): 7713 - 7723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Guerin, J. Gelfi, S. Boullier, M. Delverdier, F.-A. Bellanger, S. Bertagnoli, I. Drexler, G. Sutter, and F. Messud-Petit Myxoma Virus Leukemia-Associated Protein Is Responsible for Major Histocompatibility Complex Class I and Fas-CD95 Down-Regulation and Defines Scrapins, a New Group of Surface Cellular Receptor Abductor Proteins J. Virol., February 22, 2002; 76(6): 2912 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Seliger, U. Ritz, R. Abele, M. Bock, R. Tampe, G. Sutter, I. Drexler, C. Huber, and S. Ferrone Immune Escape of Melanoma: First Evidence of Structural Alterations in Two Distinct Components of the MHC Class I Antigen Processing Pathway Cancer Res., December 1, 2001; 61(24): 8647 - 8650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells J. Immunol., August 1, 2001; 167(3): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer zum Buschenfelde, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells J. Immunol., October 1, 2000; 165(7): 4133 - 4140. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
